BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31373223)

  • 21. Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio Are Not Prognostic Biomarkers in Rectal Cancer Patients with Curative Resection.
    Portale G; Cavallin F; Valdegamberi A; Frigo F; Fiscon V
    J Gastrointest Surg; 2018 Sep; 22(9):1611-1618. PubMed ID: 29687424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.
    Formica V; Benassi M; Del Vecchio Blanco G; Doldo E; Martano L; Portarena I; Nardecchia A; Lucchetti J; Morelli C; Giudice E; Rossi P; Anselmo A; Sileri P; Sica G; Orlandi A; Santoni R; Roselli M
    Med Oncol; 2018 May; 35(6):83. PubMed ID: 29721745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12.
    Lee JH; Kim DY; Kim SH; Cho HM; Shim BY; Kim TH; Kim SY; Baek JY; Oh JH; Nam TK; Yoon MS; Jeong JU; Kim K; Chie EK; Jang HS; Kim JS; Kim JH; Jeong BK
    Radiother Oncol; 2015 Aug; 116(2):202-8. PubMed ID: 26303015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
    Sakr A; Elsherbiny M; Abdel Moneim R; Shaaban S; Aldaly M
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1717-1723. PubMed ID: 32592369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study.
    Chung MJ; Nam TK; Jeong JU; Kim SH; Kim K; Jang HS; Jeong BK; Lee JH
    Int J Colorectal Dis; 2016 Sep; 31(9):1595-601. PubMed ID: 27464635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer.
    Kundel Y; Nasser NJ; Rath-Wolfson L; Purim O; Yanichkin N; Brenner R; Zehavi T; Nardi Y; Fenig E; Sulkes A; Brenner B
    Am J Clin Oncol; 2018 Jun; 41(6):613-618. PubMed ID: 27740975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
    Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
    Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
    J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery.
    Park JW; Lim SB; Kim DY; Jung KH; Hong YS; Chang HJ; Choi HS; Jeong SY
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):810-7. PubMed ID: 19101093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
    Araujo-Mino EP; Patt YZ; Murray-Krezan C; Hanson JA; Bansal P; Liem BJ; Rajput A; Fekrazad MH; Heywood G; Lee FC
    Oncologist; 2018 Jan; 23(1):2-e5. PubMed ID: 29158365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer.
    Li N; Dou L; Zhang Y; Jin J; Wang G; Xiao Q; Li Y; Wang X; Ren H; Fang H; Wang W; Wang S; Liu Y; Song Y
    Gastrointest Endosc; 2017 Mar; 85(3):669-674. PubMed ID: 27354104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nadir/pre-chemoradiotherapy ratio of white blood-cell count can predict tumor response and recurrence-free survival in locally advanced rectal cancer: a multi-institutional analysis.
    Lee JH; Jeong JU; Kim SH; Nam TK; Lee JH; Jeong S; Yu M; Jang HS
    Int J Colorectal Dis; 2019 Jan; 34(1):105-112. PubMed ID: 30350135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?
    Ramsay G; Ritchie DT; MacKay C; Parnaby C; Murray G; Samuel L
    Dig Surg; 2019; 36(6):495-501. PubMed ID: 30269129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy.
    Shen J; Zhu Y; Wu W; Zhang L; Ju H; Fan Y; Zhu Y; Luo J; Liu P; Zhou N; Lu K; Zhang N; Li D; Liu L
    Med Sci Monit; 2017 Jan; 23():315-324. PubMed ID: 28100902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy.
    Li Z; Li S; Ying X; Zhang L; Shan F; Jia Y; Ji J
    Gastric Cancer; 2020 May; 23(3):540-549. PubMed ID: 32072387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GRP78 Protein Expression as Prognostic Values in Neoadjuvant Chemoradiotherapy and Laparoscopic Surgery for Locally Advanced Rectal Cancer.
    Lee HY; Jung JH; Cho HM; Kim SH; Lee KM; Kim HJ; Lee JH; Shim BY
    Cancer Res Treat; 2015 Oct; 47(4):804-12. PubMed ID: 25687871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.